Clinical Trial

Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer

Study acronym: FATTAX
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 2, 2026 (before its estimated May 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-11.
Status change: Not Yet Recruiting → Recruiting 2025-12-29
Trial Details
NCT Number NCT05858398
Lead Sponsor Centre Henri Becquerel
Collaborators: Erasmus Medical Center, Universitaire Ziekenhuizen KU Leuven
Conditions Breast Cancer
Enrollment 48 participants
Start Date 2023-10-25
Primary Completion 2026-05-02 (estimated)
Study Completion 2027-05-02 (estimated)
Updated on ClinicalTrials.gov 2026-01-02